Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis: Therapeutic approaches and prognostic factors

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Zeng, Lei ^a,b   Tian, Yun Ming ^a   Huang, Ying ^a   Sun, Xue Ming ^a   Wang, Feng Hua ^a   Deng, Xiao Wu ^a   Han, Fei ^a   Lu, Tai Xiang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Jiangxi Cancer Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LIVER FAILURE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIMARY TUMOR; RETROSPECTIVE STUDY; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING; AGED; CARCINOMA; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84907584627     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108070     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Parkin DM, Bray F, Ferlay J, Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
3. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, et al. (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16: 1310-1317.
4. Lee AW, Ng WT, Chan YH, Sze H, Chan C, et al. (2012) The battle against nasopharyngeal cancer. Radiother Oncol 104: 272-278.
5. Wei WI, Sham JS. (2005) Nasopharyngeal carcinoma. Lancet 365: 2041-2054.
6. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. (1996) Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 77: 2423-2431.
7. Hui EP, Leung SF, Au JS, Zee B, Tung S, et al. (2004) Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong nasopharyngeal carcinoma study group. Cancer 101: 300-306.
8. Ong YK, Heng DM, Chung B, Leong SS, Wee J, et al. (2003) Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer 39: 1535-1541.
9. Jin Y, Cai XY, Cai YC, Cao Y, Xia Q, et al. (2012) To build a prognostic score model containing indispensible tumor markers for metastatic nasopharyngeal carcinoma in an epidemic area. Eur J Cancer 48: 882-888.
10. Khanfir A, Frikha M, Ghorbel A, Drira MM, Daoud J, et al. (2007) Prognostic factors in metastatic nasopharyngeal carcinoma. Cancer Radiotherapy 11: 461-464.
11. Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, et al. (2000) Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 18: 1324-1330.
12. Setton J, Wolden S, Caria N, Lee N. (2012) Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. Head Neck 34: 753-757.
13. Yeh SA, Tang Y, Lui CC, Huang EY. (2006) Treatment outcomes of patients with AJCC stage IVC nasopharyngeal carcinoma: benefits of primary radiotherapy. Jpn J Clin Oncol 36: 132-136.
14. Zhao C, Han F, Lu LX, Huang SM, Lin CG, et al. (2004) Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma. Ai Zheng 23: 1532-1537.
15. Luo W, Deng XW, Lu TX. (2004) Dosimetric evaluation for three dimensional radiotherapy plans for patients with early nasopharyngeal carcinoma. Ai Zheng 23: 605-608.
16. Au E, Ang PT. (1994) A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 5: 87-89.
17. Foo KF, Tan EH, Leong SS, Wee JT, Tan T, et al. (2002) Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 13: 150-156.
18. Liaw CC, Wang CH, Huang JS, Kiu MC, Chen JS, et al. (1997) Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma. Acta Oncol 36: 159-164.
19. Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, et al. (2012) Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys 82: 359-365.
20. Jin Y, Ye X, Shao L, Lin BC, He CX, et al. (2013) Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy. Eur J Cancer 49: 1619-1626.
21. An X, Wang FH, Ding PR, Deng L, Jiang WQ, et al. (2011) Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 117: 3750-3757.